Trabectedin in ovarian cancer: Could we expect more?

Annals of Oncology

Volumn 22, Issue 1, 2011, Pages 7-8

  Sessa, C ^a,b   D'Incalci, M ^c  

^a SAN GIOVANNI HOSPITAL   (Switzerland)

^b NATIONAL CANCER INSTITUTE   (Italy)

^c MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CISPLATIN; DOXORUBICIN; PACLITAXEL; PLATINUM COMPLEX; TRABECTEDIN;

ANTINEOPLASTIC ACTIVITY; CANCER GROWTH; CANCER RELAPSE; CANCER SURVIVAL; CLINICAL TRIAL; CYTOKINE PRODUCTION; DNA BINDING; EDITORIAL; HUMAN; INFLAMMATION; MYXOSARCOMA; OVARY CANCER; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RECURRENT CANCER;

EID: 78650385830     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdq641     Document Type: Editorial

References (12)

1. Bast RC, Thigpen JT, Arbuck SG et al. Clinical trial endpoints in ovarian cancer: report of an FDA/ASCO/AACR Public Workshop. Gynecol Oncol 2007; 107: 173-176.
2. Kaye S. Management of partially platinum sensitive relapsed ovarian cancer. Eur J Cancer Suppl 2008; 6: 16-21.
3. Monk BJ, Herzog TJ, Kaye SB et al. Trabectedin plus pegylated liposomal doxorubicin in recurrent ovarian cancer. J Clin Oncol 2010; 28: 3107-3114.
4. Poveda A, Vergote I, Tjulandin S et al. Trabectedin plus pegylated liposomal doxorubicin in relapsed ovarian cancer: outcomes in the partially platinum-sensitive (platinum-free interval 6-12 months) subpopulation of OVA-301 phase III randomized trial. Ann Oncol 2010; 22: 39-48.
5. Cannistra SA. Evaluating new regimens in recurrent ovarian cancer: how much evidence is good enough? J Clin Oncol 2010; 28: 3101-3103.
6. Kaye SB, Colombo N, Monk BJ et al. Trabectedin plus pegylated liposomal doxorubicin in relapsed ovarian cancer delays third-line chemotherapy and prolongs the platinum-free interval. Ann Oncol 2010; 22: 49-58.
7. Pujade-Lauraine E, Wagner U, Aavall-Lundqvist E et al. Pegylated liposomal doxorubicin and carboplatin compared with paclitaxel and carboplatin for patients with platinum-sensitive ovarian cancer in late relapse. J Clin Oncol 2010; 28: 3323-3329.
8. D'Incalci M, Galmarini CMA. Review of trabectedin (ET-743): a unique mechanism of action. Mol Cancer Ther 2010; 9(8): 2157-2163.
9. Allavena P, Signorelli M, Chieppa M et al. Anti-inflammatory properties of the novel antitumor agent yondelis (trabectedin): inhibition of macrophage differentiation and cytokine production. Cancer Res 2005; 65: 2964-2971.
10. Germano G, Frapolli R, Simone M et al. Antitumor and antiinflammatory effects of trabectedin on human myxoid liposarcoma cells. Cancer Res 2010; 70: 2235-2244.
11. Frapolli R, Tamborini E, Virdis E et al. Novel models of Myxoid Liposarcoma Xenografts mimicking the biological and pharmacological features of human tumors. Clin Cancer Res 2010; 16: 4958-4967.
12. D'Incalci M, Colombo T, Ubezio P et al. The combination of yondelis and cisplatin is synergistic against human tumor xenografts. Eur J Cancer 2003; 39(13): 1920-1926.